Nate Hill, Co-Founder & CEO of Strive Pharmacy, describes how the company approaches uncertainty around peptide inventory, ...

Real-world evidence tells you what happened. Real-World iNSIGHTS tell you why — and what to do next. A new framework for medical affairs. As the healthcare community grapples with rising obesity rates ...

During his conversation, Cziraky discussed shifts in how RWD is perceived and how companies are viewing it as a different kind of asset. Mark Cziraky: The core issues always come back to privacy, ...

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...

Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...

GSK intends to move its mRNA seasonal influenza vaccine candidate to a Phase III efficacy trial starting in September. The move is based on presented positive Phase II data for it ...

Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research environments.

Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research ...

In March of this year, ACTO co-founder and CEO Parth Khanna wrote a piece for Pharmaceutical Executive discussing an area where he sees AI making a major impact. According to him, digital health ...

Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...

There is a myth in our industry that when an RBQM implementation fails to deliver the cause must be technical. It was the ...

Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer ...